## Biologics \& Biosimilars: Impact of <br> Amgen and Hot Topics in <br> Biosimilar Litigation

Wednesday, February 7, 2024 Kramer Levin Naftalis \& Frankel LLP

Mark with an $X$ the appropriate boxes in rating the following aspects of the program facilities.

|  |  | Excellent | Good | Fair | Poor |
| ---: | ---: | ---: | :---: | :---: | :---: |
| Facility | $\square$ | $\square$ | $\square$ | $\square$ |  |
| Technology | $\square$ | $\square$ | $\square$ | $\square$ |  |
| Registration | $\square$ | $\square$ | $\square$ | $\square$ |  |
| Refreshment | $\square$ | $\square$ | $\square$ | $\square$ |  |
|  | Overall Program | $\square$ | $\square$ | $\square$ | $\square$ |

Mark with an X the appropriate boxes in rating the following aspects of the program.

|  |  | Excellent | Good | Fair | Poor |
| :--- | :--- | :---: | :---: | :---: | :---: |
|  | Written Materials | $\square$ | $\square$ | $\square$ | $\square$ |
| Larry Coury, Regeneron | Quality of Presentation | $\square$ | $\square$ | $\square$ | $\square$ |
| Mira Mulvaney, Eli Lilly and Company | Quality of Presentation | $\square$ | $\square$ | $\square$ | $\square$ |
| Jen Reda, Johnson \& Johnson | Quality of Presentation | $\square$ | $\square$ | $\square$ | $\square$ |
| Irena Royzman, Kramer Levin Naftalis \& Frankel LLP | Quality of Presentation | $\square$ | $\square$ | $\square$ | $\square$ |

## Areas for improvement and additional comments.

1. What segments of the program were of most value to you?
2. What segments of the program were of least value to you?
3. Comments:
4. How did you first learn about this program?

NYIPLA Website E-mail
Social Media
Word of Mouth

Other: $\qquad$

Thank you for participating!
PLEASE HAND IN COMPLETED EVALUATION FORM OR EMAIL TO ADMIN@NYIPLA.ORG.
Materials are available online at:
https://www.nyipla.org/assnfe/ev.asp?ID=1509

